EMCURE PHARMACEUTICALS
|
EMCURE PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 27.50 | 29.42 | 36.62 | 21.68 | 4.62 |
| CEPS(Rs) | 46.37 | 45.45 | 52.39 | 41.02 | 23.30 |
| DPS(Rs) | 3.00 | 2.00 | 3.00 | 1.00 | 2.50 |
| Book NAV/Share(Rs) | 162.17 | 137.48 | 109.02 | 125.04 | 104.23 |
| Tax Rate(%) | 27.45 | 24.81 | 27.76 | 36.32 | 4.49 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 18.12 | 19.37 | 22.24 | 19.71 | 13.49 |
| EBIT Margin(%) | 14.21 | 15.76 | 19.21 | 13.69 | 6.94 |
| Pre Tax Margin(%) | 10.72 | 12.25 | 16.27 | 10.52 | 2.02 |
| PAT Margin (%) | 7.77 | 9.21 | 11.75 | 6.70 | 1.93 |
| Cash Profit Margin (%) | 12.38 | 13.48 | 15.84 | 11.87 | 8.08 |
| Performance Ratios | |||||
| ROA(%) | 7.39 | 8.97 | 11.15 | 6.72 | 1.79 |
| ROE(%) | 19.45 | 25.21 | 33.19 | 20.19 | 5.43 |
| ROCE(%) | 19.87 | 21.97 | 26.56 | 19.75 | 9.00 |
| Asset Turnover(x) | 0.95 | 0.97 | 0.95 | 1.00 | 0.93 |
| Sales/Fixed Asset(x) | 1.53 | 1.68 | 1.62 | 1.67 | 1.57 |
| Working Capital/Sales(x) | 6.50 | 7.47 | 13.02 | 20.21 | -24.07 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.65 | 0.60 | 0.62 | 0.60 | 0.64 |
| Receivable days | 94.32 | 88.49 | 84.97 | 76.52 | 74.07 |
| Inventory Days | 78.21 | 84.77 | 90.46 | 78.47 | 80.50 |
| Payable days | 193.72 | 194.85 | 188.82 | 132.95 | 137.31 |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | - |
| PCE(x) | - | - | - | - | - |
| Price/Book(x) | - | - | - | - | - |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.30 | 0.32 | 0.33 | 0.32 | 0.43 |
| EV/Core EBITDA(x) | 1.57 | 1.55 | 1.40 | 1.55 | 2.78 |
| EV/EBIT(x) | 2.10 | 1.98 | 1.69 | 2.30 | 6.04 |
| EV/CE(x) | 0.40 | 0.41 | 0.48 | 0.43 | 0.54 |
| M Cap / Sales | - | - | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 11.23 | 2.23 | -3.32 | 19.96 | 7.02 |
| Core EBITDA Growth(%) | 4.86 | -11.93 | 9.94 | 61.19 | -6.83 |
| EBIT Growth(%) | 0.37 | -16.34 | 34.26 | 136.36 | -34.58 |
| PAT Growth(%) | -6.10 | -20.03 | 67.84 | 316.06 | -51.91 |
| EPS Growth(%) | -6.51 | -19.66 | 68.87 | 369.04 | -57.14 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.71 | 0.88 | 1.05 | 1.02 | 1.15 |
| Current Ratio(x) | 1.33 | 1.27 | 1.15 | 1.09 | 0.93 |
| Quick Ratio(x) | 0.85 | 0.81 | 0.67 | 0.65 | 0.52 |
| Interest Cover(x) | 4.07 | 4.50 | 6.53 | 4.32 | 1.41 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of EMCURE PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| EMCURE PHARMACEUTICALS | ₹18,075.5 Cr | -6.9% | -2.3% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹409,123.0 Cr | -1.3% | 4.7% | 3.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹152,173.0 Cr | 1.9% | 1.5% | 41.9% | Stock Analytics | |
| CIPLA | ₹119,640.0 Cr | 3.4% | 0.1% | -3.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹109,154.0 Cr | -4.8% | 1.9% | 20.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,446.4 Cr | -0.1% | -1% | -11.3% | Stock Analytics | |
EMCURE PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| EMCURE PHARMACEUTICALS | -6.9% |
-2.3% |
|
| SENSEX | 1.8% |
3.5% |
2.7% |
You may also like the below Video Courses
